Navigation Links
Cambrex Reports Third Quarter 2013 Financial Results
Date:11/1/2013

should call 1-888-510-1765 for domestic and +719-325-2494 for international.  Please use the pass code 8702967 and call approximately 10 minutes prior to start time.  A webcast will be available on the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Friday, November 8, 2013 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 8702967 to access the replay. 

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.Forward Looking Statements
This document contains "forward-looking statements," including statements regarding expected performance, especially those set forth under the heading "Financial Expectations – Continuing Operations," including the Company's expectation that full year 2013 sales, excluding the impact of foreign currency, will increase between 9% and 12% versus 2012, that full year 2013 adjusted EBITDA will be between $64 and $68 million, that capital expenditures will be approximately $40 to $43 million, that depreciation will be $22 to $24 million in 2013, that the Company currently expects to pay only a small amount of cash taxes in the U.S. for the next few years, and that its estimated tax rate will be between 3
'/>"/>

SOURCE Cambrex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cambrex Reports Fourth Quarter And Full Year 2012 Financial Results
2. Cambrex To Announce Fourth Quarter 2012 Financial Results On February 6, 2013
3. Cambrex Reports Third Quarter 2012 Financial Results
4. Cambrex to Announce Third Quarter 2012 Financial Results on October 31, 2012
5. Cambrex Announces Significant New Supply Agreement
6. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
7. Cambrex Reports First Quarter 2012 Results
8. IRIDEX Reports 2013 Third Quarter Results
9. Perrigo Reports Record First Quarter Revenue, Adjusted Earnings And Margins
10. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2014 And Announces ARRY-520 Development Strategy
11. Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
(Date:7/12/2014)... July 12, 2014 Demand Response Management ... considerable benefits in reducing the imbalance between energy supply ... appliances have been rolled out (due to increasing pressure ... (AMI). This helps in controlling residential appliances and thermostats ... in the North American region, and with government mandates ...
(Date:7/12/2014)... make exercise fun, you,ll eat less after your workout, new ... on a 1.4-mile walk and were either told it would ... were given lunch after the walk, and those who were ... chocolate pudding for dessert than those who were told it ... were given mid-afternoon snacks after their walk. Those who were ...
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... 12, 2014 “Critical Care Therapeutics ... and Late-Stage Four-Factor PCCs and Recombinant Products to ... critical care market in the US, UK, France, ... provides an estimation of market size for 2013, ... critical care indications that are being treated using ...
(Date:7/12/2014)... A recent article released by Seattle's well ... suggestions for those seeking cosmetic surgical procedures in summer ... and the heat begins to enliven the rainy Pacific Northwest, ... realizing that they didn’t work out as much during the ... a sudden surge of people eager to look their best ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... as 10-fold, researchers find, , MONDAY, Sept. 7 (HealthDay ... minor infection can double the rate of memory loss, ... found that Alzheimer,s patients who had respiratory, gastrointestinal or ... can have high levels of tumor necrosis factor-alpha (TNF-a), ...
... minor complications seen with ,after-hours, procedures, study finds , ... daytime slot to undergo an orthopedic procedure may lower ... a new study has found. , The study, ... of Bone and Joint Surgery , found little difference ...
... 7 Bounty, the UK,s favourite parenting,club, today launches a 4 ... mums take a real life, close up peek at how a ... To view the Multimedia News Release, please click: , ... Breastfeeding is the healthiest and most natural way to feed a ...
... , , , ... Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell ... its breakthrough stem cell and related technology. The Jordanian Stem ... purchase the technology from Stemedica,s wholly-owned subsidiary, Stemedica International, S.A. ...
... in clearance of amyloid plaque from brain , SUNDAY, ... scientists have uncovered three gene variants that up the ... dementia among the elderly and the seventh-leading cause of ... Dr. Philippe Amouyel of the Institut Pasteur de Lille ...
... ... the grand opening of the new rehabilitation hospital with partner HealthSouth. , ... Mesa, Ariz. (PRWEB) September 6, ... on August 18 to welcome the rehabilitation hospital to the East Valley and ...
Cached Medicine News:Health News:Even Mild Infections Hasten Decline With Alzheimer's 2Health News:Even Mild Infections Hasten Decline With Alzheimer's 3Health News:Let Orthopedic Surgery Wait Until Morning When Possible 2Health News:Bounty Parenting Club Launches View on Demand 'How to Breastfeed' Video 2Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 2Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 3Health News:Trio of Gene Variants Discovered That May Raise Alzheimer's Risk 2Health News:Trio of Gene Variants Discovered That May Raise Alzheimer's Risk 3Health News:ATSU Arizona Health & Technology Park Partner HealthSouth Holds Grand Opening 2
... Pro Osteon Bone Graft Substitutes a natural ... from cadaver bone, but such grafts may ... disease transmission. Interpore Cross has developed the ... to address these needs, offering surgeons a ...
... Healos is an osteoconductive matrix constructed ... fully coated with hydroxyapatite through a ... with autogenous bone marrow aspirate, Healos ... cell attachment, proliferation and differentiation. The ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Sharp Weitlaner Retractor....
Medicine Products: